</s> backgroundhuman papillomavirus (hpv ) is licensed for use in the united states. 
 routine vaccination at age 11 or 12 years has been recommended by the advisory committee on immunization practices ( ACIP ) since 2006 for females and since 2011 for males. this report provides recomendations and guidance regarding use of HPV vaccines and updates recommendations for use of a 2-dose schedule for girls and boys who initiate the vaccination series at ages 9 through 14 years and for immunocompromised persons.methodsa systematic review was conducted to identify studies involving human subjects* that reported primary data on any important or critical health outcomes related to HPV vaccination.resultsthe review focused on immunogenicity, efficacy, and postlicensure effectiveness after 2 doses of 9-valent or bivalent vaccine, administered at an interval of 0 and 6 months (Â±4 weeks).conclusions and recommendationsfor use of 2- and 3-dose schedules for HPV vaccination, this report updates recommendations previously published in 2014 and 2015. </s>